Mind over fatigue: new study tests meditation and yoga for blood cancer patients
NCT ID NCT03735992
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a mind-body group program can help reduce fatigue in people who have finished treatment for blood cancers like leukemia or lymphoma. The program includes relaxation, gentle exercise, and stress management techniques. Researchers will compare fatigue levels between those who take the program and those who don't, with 94 participants total.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- mind-body group program (based on MBSR and mind-body medicine)
- What this could lead to
- If it works, this could offer a drug-free way to manage fatigue and improve quality of life for blood cancer survivors.
- What could go wrong
- This is a small, early-stage trial with no blinding, so results may be influenced by placebo effects. The program requires significant time commitment and may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 94 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2017
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with malignant hematological diseases in complete remission after primary chemotherapy and/or radiation * Physical and mental ability to attent 8 of 11 group units Exclusion Criteria: * Chemotherapy, radiation, or rehabilitation programm during the study period * Pregnancy * Participation in other studies with behavioral interventions during the study period
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hematologic neoplasms are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Robert-Bosch-Krankenhaus, Abteilung für Hämatologie, Onkologie und Palliativmedizin
RECRUITINGStuttgart, 70376, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ultrasound may reveal hidden bone damage in blood cancers
- Blood cancer patients may need higher antibiotic doses to beat superbugs
- New antibody may offer safer shield against transplant complications
- Could a 30-Day habit shift help blood cancer patients regain control?
- Experimental blood cancer drug KK2430 enters first human tests
- New hope for tough blood cancers? early trial launches